https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53619 Wed 07 Feb 2024 14:40:08 AEDT ]]> A randomised controlled trial of acceptance and commitment therapy for anxious adolescents: effectiveness and mechanisms for change https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22451 Wed 05 Dec 2018 17:46:53 AEDT ]]> Personality traits as mediators of the relationship between childhood trauma and depression severity in bipolar disorder: A structural equation model https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51127 Tue 22 Aug 2023 15:51:17 AEST ]]> The relationship between mental health disorders and treatment outcomes among adults who stutter https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7287 Sat 24 Mar 2018 08:42:14 AEDT ]]> Community-dwelling stroke survivors: function is not the whole story with quality of life https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10516 Sat 24 Mar 2018 08:13:56 AEDT ]]> Down-titration from high-dose combination therapy in asthma: removal of long-acting β₂-agonist https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10770 Sat 24 Mar 2018 08:13:53 AEDT ]]> Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> Mechanisms of change: exploratory outcomes from a randomised controlled trial of acceptance and commitment therapy for anxious adolescents https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27174 Sat 24 Mar 2018 07:31:43 AEDT ]]> Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52301 Mon 09 Oct 2023 10:16:59 AEDT ]]> Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52306 Mon 09 Oct 2023 10:16:43 AEDT ]]> Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54830 Fri 15 Mar 2024 11:53:47 AEDT ]]>